Verified source report
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
What happened
According to STAT’s source item, STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study, Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-05-25T12:45:00+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early studySTAT - 2026-05-25T12:45:00+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.